539206 — Genomic Valley Biotech Income Statement
0.000.00%
- IN₹189.38m
- IN₹185.20m
- IN₹1.65m
Annual income statement for Genomic Valley Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8.47 | 2.08 | 0.706 | 27.2 | 1.65 |
Cost of Revenue | |||||
Gross Profit | 9.14 | 1.26 | 0.686 | 11.4 | — |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 4.65 | 5.32 | 1.08 | 21.2 | 1.51 |
Operating Profit | 3.82 | -3.24 | -0.375 | 6.06 | 0.136 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2.06 | -5.02 | -0.016 | 6.49 | 0.151 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.86 | -5.59 | -0.093 | 6.48 | 0.152 |
Net Income Before Extraordinary Items | |||||
Net Income | 2.86 | -5.59 | -0.093 | 6.48 | 0.152 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.86 | -5.59 | -0.093 | 6.48 | 0.152 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.936 | -1.83 | -0.923 | 2.99 | 0.05 |
Dividends per Share |